设为首页 加入收藏

TOP

Rebif 44 micrograms solution for injection in pre-filledsyri
2014-04-21 10:38:36 来源: 作者: 【 】 浏览:363次 评论:0

For doctors

 

What is it and how is it used?

Rebif belongs to a class of medicines known as interferons. These are natural substances that transmit messages between cells. Interferons are produced by the body and play an essential role in the immune system. Through mechanisms that are not totally understood, interferons help to limit the damage of the central nervous system associated with multiple sclerosis.

Rebif is a highly purified soluble protein that is similar to the natural interferon beta that is produced in the human body.

Rebifis used for the treatment of multiple sclerosis. It has been shown to reduce the number and the severity of relapses and to slow the progression of disability.

What do you have to consider before using it?

Do not use Rebif

if you are allergic hypersensitive to natural or recombinant interferon beta or any of the other ingredients of Rebif, if you are pregnant see Pregnancy and breast-feeding, if you are severely depressed at present.

Take special care with Rebif

Rebif should only be used under the supervision of your doctor. Before treatment with Rebif, read carefully and follow the advice given under How to use Rebif in order to minimise the risk of injection site necrosis skin breakdown and tissue destruction that has been reported in patients treated with Rebif. If you experience troubling local reactions, contact your doctor. Before treatment with Rebif, advise your doctor if you have an allergy hypersensitivity to any other medicines.

Inform your doctor if you have a disease of the bone marrow, kidney, liver, heart, thyroid, or if you have experienced depression, or if you have any history of epileptic seizures, so that heshe can closely monitor your treatment and any worsening of these conditions.

Using other medicines

Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including medicines obtained without a prescription.
In particular you should tell your doctor if you are using antiepileptics or antidepressants.

Pregnancy and breast-feeding

You must not start treatment with Rebif if you are pregnant. While taking Rebif, you must use effective methods of contraception if you are a woman of child-bearing potential. If you become pregnant or plan to become pregnant while using Rebif ask your doctor for advice.

Prior to taking the medicine, please inform your doctor if you are breast-feeding. The use of Rebif is not recommended if you are breast-feeding.

Driving and using machines

Effects of the disease itself or of its treatment might influence your ability to drive or to use machines. You should discuss this with your doctor if you are concerned.

Important information about some of the ingredients of Rebif

This medicinal product contains 2.5 mg benzyl alcohol per dose.
Must not be given to premature babies or neonates.
May cause toxic reactions and allergic reactions in infants and children up to 3 years old.

How is it used?

Always use Rebif exactly as your doctor has told you. You should check with your doctor if you are not sure.

Dose
The usual dose is 44 micrograms (12 million IU) given three times per week for adults and adolescents from 16 years of age. A lower dose of 22 micrograms (6 million IU) given three times per week is recommended for:
- patients who cannot tolerate the higher dose.
- adolescents from the age of 12 years.

Rebif should be administered, if possible:
- three times per week
- on the same three days (at least 48 hours apart)
- at the same time (preferably in the evening).

Method of administration
Rebif is intended for subcutaneous (under the skin) injection.
The first injection(s) must be performed under the supervision of an appropriately qualified healthcare professional. After receiving adequate training, you, a family member, friend or carer can use Rebif syringes to administer the medicine at home. It may also be administered with a suitable auto-injector.

For administration of Rebif, please read the following instructions carefully:

This medicinal product is for single use.
Only clear to opalescent solution without particles and without visible signs of deterioration should be used.

How to inject Rebif
- Choose an injection site. Your doctor will advise you on the possible injection sites (good sites include the upper thighs and the lower abdomen). Hold the syringe like a pencil or dart. It is recommended that you keep track of and rotate your injection sites, so that one area is not injected too frequently in order to minimise the risk of injection site necrosis. NOTE: do not use any areas in which you feel lumps, firm knots, or pain; talk to your doctor or healthcare professional about anything you find.
- Wash your hands thoroughly with soap and water.
- Remove the Rebif syringe from the blister pack by peeling back the plastic covering. - Before the injection, use an alcohol wipe to clean the skin at the injection site. Let the skin dry. If a bit of alcohol is left on the skin, you may get a stinging sensation.

Gently pinch the skin together around the site to lift it up a bit. Resting your wrist on the skin near the site, stick the needle at a right angle straight into the skin with a quick, firm motion. Inject the medicine by using a slow, steady push push the plunger all the way in until the syringe is empty. Hold a swab on the injection site. Remove the needle from the skin.

Gently massage the injection site with a dry cotton ball or gauze. Dispose of all used items once you have finished your injection, immediately discard the syringe in an appropriate disposal unit.

If you use more Rebif than you should

In case of overdose, contact your doctor immediately.

If you forget to use Rebif

If you miss a dose, continue to inject from the day of the next scheduled dose. Do not take a double dose to make up for a forgotten dose.

If you stop using Rebif

The effects of Rebif may not be noticed immediately. Therefore you should not stop using Rebif but continue to use it regularly to achieve the desired result. If you are uncertain about the benefits, please consult your doctor.

You should not discontinue the treatment without first contacting your doctor.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

What are possible side effects?

Like all medicines, Rebif can cause side effects, although not everybody gets them.

Tell your doctor immediately and stop using Rebif if you experience any of the following serious side effects:

Serious allergic hypersensitivity reactions. If, immediately following Rebif administration you experience a sudden difficulty breathing, which may appear in association with swelling of face, lips, tongue or throat, nettle rash, itching all over the body, and a feeling of weakness or faintness, contact your doctor immediately or seek urgent medical attention.

Inform your doctor immediately if you experience any of the following possible symptoms of a liver problem jaundice yellowing of the skin or of the whites of the eyes, widespread itching, loss of appetite accompanied by nausea and vomiting and easy bruising of the skin. Severe liver problems can be associated with additional signs, e.g. difficulty concentrating, sleepiness and confusion.

If you feel very depressed or develop thoughts of suicide, report it immediately to your doctor.

Side effects may occur with certain frequencies, which are defined as follows very common affects more than 1 user in 10 common affects 1 to 10 users in 100 uncommon affects 1 to 10 users in 1,000 rare affects 1 to 10 users in 10,000 very rare affects less than 1 user in 10,000 not known frequency cannot be estimated from the available data.

Flu-like symptoms, such as headache, fever, chills, muscle and joint pains, fatigue and nausea are very common. These symptoms are usually mild, are more common at the start of the treatment and decrease with continued use. To help reduce these symptoms your doctor may advise you to take a fever reducing painkiller before a dose of Rebif and then for 24 hours after each injection.

Injection site reactions including redness, swelling, discoloration, inflammation, pain and skin breakdown are very common. The occurrence of injection site reactions usually decreases over time. Tissue destruction necrosis, abscess and mass at injection site are uncommon. See recommendations in section Take special care with Rebif to minimise the risk of injection site reactions. The injection site can become infected frequency not known the skin may become swollen tender and hard and the whole area could be very painful. If you experience any of these symptoms, contact your doctor for advice.

Certain laboratory tests may change very common. These changes are generally not noticed by the patient no symptoms, are usually reversible and mild, and most often do not require particular treatment. The number of red blood cells, white blood cells or platelets may decrease. Possible symptoms resulting from these changes could include tiredness, reduced ability to fight infection, bruising or unexplained bleeding. Liver function tests may be disturbed. Inflammation of the liver has also been reported frequency not known. If you experience symptoms suggesting a liver disorder, such as loss of appetite accompanied by other symptoms such as nausea, vomiting, jaundice, please contact your doctor immediately see above Tell your doctor immediately....

Depression is common in treated patients with multiple sclerosis. If you feel depressed, please contact your doctor immediately.

Thyroid dysfunction is uncommon. The thyroid gland may function either excessively, or insufficiently. These changes in the thyroid activity are almost always not felt by the patient as symptoms, however your doctor may recommend testing as appropriate.

MS pseudo-relapse frequency not known There is a possibility that at the beginning of your treatment with Rebif you may experience symptoms that resemble those of a multiple sclerosis relapse. For example, your muscles may feel very tense or very weak, preventing you from moving as you want. In some cases such symptoms are associated with fever or flu-like symptoms described above. If you notice any of these side effects talk to your doctor.

Other possible side effects include:

Very common:
- Headache

Common Insomnia sleeping difficulty Diarrhoea, nausea, vomiting Itching, rash skin eruptions Muscle and joints pain Fatigue, fever, chills

Frequency not known Allergic hypersensitivity reactions Face swelling, hives Suicide attempt Epileptic seizures Serious skin reactions - some with mucosal lesions Liver inflammation hepatitis Hair loss Breathing difficulties Blood clots such as deep venous thrombosis Disorders of the retina back of the eye such as inflammation or blood clots with consequent vision disorders vision disturbances, loss of vision Thrombotic thrombocytopenic purpura Haemolytic uremic syndrome a disorder that may present with small blood clots, increased bruising, bleeding, decreased platelets, anaemia, extreme weakness, and renal disorders.

The following side effects were reported for interferon beta frequency not known Dizziness Nervousness Loss of appetite Dilatation of the blood vessels and palpitation Irregularities andor changes in menstrual flow.

You should not stop or alter the medication without your doctor’s advice.

If any of the side effects gets serious, or if you notice any side effects not mentioned in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.

Do not use Rebif after the expiry date which is stated on the label after EXP.

Store in a refrigerator (2°C – 8°C).

Do not freeze. (To prevent accidental freezing, avoid placing near the freezer compartment).

For the purpose of ambulatory use, you may remove Rebif from the refrigerator and store it not above 25°C for one single period of up to 14 days. Rebif must then be returned to the refrigerator and used before the expiry date.

Store in the original package in order to protect from light.

Do not use Rebif if you notice any visible signs of deterioration such as if the solution is no longer clear or if it contains particles.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

↑ back to table of contents ↑

For doctors

What is it?

Rebif is a solution for injection in prefilled syringes, prefilled pens and cartridges. The syringes and pens contain 8.8, 22 or 44 micrograms of the active substance, interferon beta-1a. The cartridges contain a total of 66 or 132 micrograms of interferon beta-1a and are designed for multiple dosing using an electronic injection device that delivers 8.8, 22 or 44 micrograms per dose.

What is it used for?

Rebif is used to treat patients aged 12 years and over with relapsing multiple sclerosis (MS). This is the type of MS where the patient has attacks (relapses) in between periods with no symptoms. Rebif’s effectiveness has not been shown in patients with secondary progressive MS (the type of MS that comes after relapsing MS) that is not relapsing.

The medicine can only be obtained with a prescription.

How is it used?

Rebif treatment should be started by a doctor who has experience in the management of MS.

The recommended dose of Rebif is 44 micrograms given three times a week by injection under the skin. The 22-microgram dose is recommended for patients who cannot tolerate the higher dose and for patients aged between 12 and 16 years.

When first starting treatment with Rebif, the dose should be slowly increased to avoid side effects, starting with 8.8 micrograms three times a week for the first two weeks, followed by 22 micrograms three times a week for the next two weeks. Special packs with the correct quantities of syringes or cartridges are available when starting treatment. The electronic injection device used with the cartridges is programmed to deliver the correct doses of Rebif at the start of treatment and during the standard-dose phase.

The patients can inject Rebif themselves if they have been trained appropriately. The doctor may advise the patient to take a fever-reducing painkiller before each injection and for 24 hours after injection to reduce the influenza (flu)-like symptoms that may occur as a side effect of treatment. All patients should be assessed at least once every two years.

How does it work?

MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves. This is called ‘demyelination’. The active substance in Rebif, interferon beta-1a, belongs to the group ‘interferons’. Interferons are natural substances produced by the body to help it fight against attacks such as infections caused by viruses. The exact way that Rebif works in MS is not yet fully understood but interferon beta seems to calm the immune system down and prevent relapses of MS.

Interferon beta-1a is produced by a method known as ‘recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce interferon beta-1a. The replacement interferon beta-1a acts in the same way as naturally produced interferon beta.

How has it been studied?

Rebif has been studied in 560 patients with relapsing MS. The patients had experienced at least two relapses in the previous two years. Patients received either Rebif (22 or 44 micrograms) or placebo (a dummy treatment) for two years. The study was then extended to four years. The main measure of effectiveness was the number of relapses that the patients had.

Rebif has also been studied in patients with secondary progressive MS. The study looked at the ability of the medicine to prevent the progression of disability over three years.

The company has not carried out any formal studies of patients under 16 years of age. However, it presented information from published studies on the use of Rebif in patients aged between 12 and 18 years.

What benefits has it shown during the studies?

Rebif was more effective than placebo in reducing the number of relapses in relapsing-remitting MS. Relapses were reduced by about 30% over two years for both Rebif 22 and 44 micrograms compared with placebo, and by 22% (Rebif 22 micrograms) and 29% (Rebif 44 micrograms) over four years.

In the study of patients with progressive MS, Rebif had no significant effect on the progression of disability, but the relapse rate was reduced by about 30%. Some effect on progression of disability could be seen, but only in the patients who had relapses in the two years before the start of the study.

In patients aged between 12 and 18 years, the published studies showed that the patients had a decrease in the rate of relapse. This may be due to Rebif treatment.

What is the risk associated?

The most common side effects with Rebif (seen in more than 1 patient in 10) are flu-like symptoms, neutropenia, lymphopenia and leucopenia (low white blood cell counts), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), headache, inflammation and other reactions at the injection site, and increases in transaminases (liver enzymes). For the full list of all side effects reported with Rebif, see the package leaflet.

Rebif should not be used in people who have a history of hypersensitivity (allergy) to natural or recombinant interferon beta, or any of the other ingredients. Rebif treatment must not be started during pregnancy. If a woman becomes pregnant while taking the medicine, she should consult her doctor. Rebif must also not be used in patients who are suffering from severe depression or having thoughts about committing suicide.

Why has it been approved?

The CHMP decided that Rebif’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Further information

The European Commission granted a marketing authorisation valid throughout the European Union for Rebif to Merck Serono Europe Limited on 4 May 1998. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Rebif, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This summary was last updated in 06-2010.

↑ back to table of contents ↑
 

Name

 

Rebif 44 micrograms solution for injection in pre-filled
syringe

 

Composition

 

Each pre-filled syringe (0.5 ml) contains 44 micrograms (12 MIU*) of interferon beta-1a**.

* Million International Units, measured by cytopathic effect (CPE) bioassay against the in house IFN beta-1a standard which is calibrated against the current international NIH standard (GB-23-902-531).
** produced in Chinese hamster ovary Cells (CHO-K1) by recombinant DNA technology.

Excipient: 2.5 mg benzyl alcohol
For a full list of excipients, see section 6.1.

 

Pharmaceutical Form

 

Solution for injection in pre-filled syringe.
Clear to opalescent solution, with pH 3.5 to 4.5 and osmolarity 250 to 450 mOsm/l.

 

Are you an Healthcare Professional? Access professional drug leaflets on Diagnosia.com!

 

以下是“全球医药”详细资料
Tags: 责任编辑:admin
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Rebif Solution for Injection in.. 下一篇Rebif 44 micrograms/0.5ml solut..

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位